Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bavarian Nordic’s RSV Vax Achieves Positive Results | Contract Pharma
Trials & Filings

Bavarian Nordic’s RSV Vax Achieves Positive Results

Analysis suggests that the vaccine has the desired effect of boosting memory responses against RSV

Bavarian Nordic achieved positive data from its Phase II study investigating the safety and immune effects of its universal RSV vaccine, MVA-BN RSV in an older adult population. 

In a planned follow-up analysis, there was an approximately 1.5-fold increase in IgA antibodies over baseline levels, with peak increases seen in the weeks immediately following vaccination. The boosting effect was more pronounced in individuals with a lower baseline mucosal IgA at the time of vaccination. This observation suggests that the vaccine has the desired effect of boosting memory responses against RSV in patients with a poor underlying immunity. 

MVA-BN RSV has been specifically designed to mimic a natural RSV infection, and can boost the body’s memory response against RSV. The vaccine has been shown to elicit T-cells and humoral antibodies against each of the 5 targets encoded in the vaccine, as well as the whole virus. Previously reported data demonstrated that the vaccine induced sustained protection levels for up to 6 months, the duration of an RSV season, against all 5 encoded targets when compared to a placebo.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters